Targeted panel targeting 83 RNA fusions from FFPE tissue across multiple solid tumor types.
Assay time
Hands-on time
Input quantity
The Pillar oncoReveal Multi-Cancer RNA Fusion v2 Panel is a robust NGS assay designed to interrogate 18 driver genes and 83 fusion partners relevant across multiple solid tumor types using RNA isolated from formalin-fixed, paraffin-embedded (FFPE) samples.
This focused panel can detect gene rearrangements in RNA isolated from FFPE tissue.
The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
The workflow allows labs to maintain control of samples and results with single-tube, tiled amplification that can be performed in-house by any NGS lab.
| Assay time | 48 hours from sample to report |
|---|---|
| Cancer type | Pan-cancer, Solid tumor |
| Content specifications | 18 driver genes and 83 fusion partners |
| Description | RNA fusion panel interrogating 18 driver genes and 83 fusion partners from FFPE tissue |
| Hands-on time | ~3 hr |
| Input quantity | 10–50 ng RNA |
| Instruments | MiSeq System, iSeq 100 System, NextSeq 550 System, MiSeqDx in Research Mode, MiniSeq System, NextSeq 550Dx in Research Mode, MiSeq i100 System |
| Method | Amplicon sequencing, Targeted RNA sequencing |
| Nucleic acid type | RNA |
| Number of amplicons | Pool 1: 83 amplicons |
| Number of reactions | 24 reactions per kit |
| Specialized sample types | FFPE tissue |
| Species category | Human |
| Strand specificity | Non-stranded |
| Target insert size | 120 bp |
| Technology | Sequencing |
| Variant class | Gene fusions |
The Pillar oncoReveal Multi-Cancer RNA Fusion v2 Panel also requires the use of a Pillar index kit, sequencing reagents, and DRAGEN Amplicon or PiVAT secondary analysis software. If additional variant interpretation is desired, Illumina Connected Insights is recommended.
The Pillar oncoReveal Multi-Cancer RNA Fusion v2 Panel analyzes multiple solid tumor types using RNA isolated from FFPE samples in under 9 hours with approximately 3 hours of hands-on time.
Pillar oncoReveal Multi-Cancer RNA Fusion v2 Panel
Liquid biopsy for cancer biomarker research
Researchers can use liquid biopsy NGS assays to detect and characterize tumor-derived biomarkers present in the blood of individuals with cancer.
Advancing cancer research through NGS
Our sequencing and microarray technologies support a broad range of cancer genomics research applications, from DNA to RNA analysis, epigenetics, and more.
Detecting changes in the cancer transcriptome
Detect cancer gene expression and transcriptome changes and identify novel cancer transcripts with RNA next-generation sequencing (RNA-Seq).
| Pillar oncoReveal Multi-Cancer RNA Fusion v2 Panel | Pillar oncoReveal Solid Tumor v2 Panel | Pillar oncoReveal Multi-Cancer CNV + RNA Fusion Panel | TruSight RNA Pan-Cancer Panel | |
|---|---|---|---|---|
| Assay time | 48 hours from sample to report | 48 hours from sample to report | 48 hours from sample to report | 2.5 days |
| Content specifications | 18 driver genes and 83 fusion partners | 48 genes | 78- gene small pan-tumor oncology panel | Pan-cancer panel with 1,385 targeted genes and 21,043 targeted exonic regions. Includes 507 genes involved in cancer gene fusions. |
| Hands-on time | ~3 hr | ~3 hr | ~3 hr | 11 hr |
| Input quantity | 10–50 ng RNA | 20–80 ng DNA | 5–80 ng DNA, 10–50 ng RNA | 10 ng total RNA, 20–100 ng FFPE RNA |
| Method | Amplicon sequencing, Targeted RNA sequencing | Targeted DNA sequencing, Amplicon sequencing | Targeted DNA sequencing, Amplicon sequencing, Targeted RNA sequencing | Targeted RNA sequencing, Target enrichment, Custom sequencing |
| Nucleic acid type | RNA | DNA | DNA, RNA | RNA |
| Number of reactions | 24 reactions per kit | 24 reactions per kit | 24 DNA/24 RNA | |
| Specialized sample types | FFPE tissue | FFPE tissue | Blood, Low-input samples, FFPE tissue | Low-input samples, FFPE tissue |
| Species category | Human | Human | Human | Human |
| Technology | Sequencing | Sequencing | Sequencing | Sequencing |
Library Prep & Array Kit Selector
Find the right sequencing library preparation kit or microarray for your needs. Filter by method, species, and more. Compare, share, and order kits.
Gene List
Pillar oncoReveal Multi-Cancer RNA Fusion v2 Panel includes 18 driver genes and 83 partners.
Panel Specifications
Pillar oncoReveal Multi-Cancer RNA Fusion v2 Panel specifications for interrogation of fusion transcripts (RNA) isolated from FFPE tissue.
oncoReveal™ MultiCancer RNA Fusion v2 Pnl 24rxn
HRA-HS-1002-24
18 gene (24 sample) solid tumor RNA panel on SLIMamp™ workflow
List Price:
Discounts:
Indices PI501-8, PI701-4 (32 combinations, 96 reactions)
IDX-PI-1001-96
Indices PI501-8, PI701-4 (32 combinations, 96 reactions)
List Price:
Discounts:
Kit D, indices PI501-8, PI701-12
IDX-PI-1004-192
Kit D, indices PI501-8, PI701-12
List Price:
Discounts:
Showing of
Product
Qty
Unit price
Product
Catalog ID
Quantity
Unit price
Simplified operations, advanced chemistry, and onboard informatics provide an easy-to-use, fast, and flexible instrument supporting a broad range of applications.
Reagents for the MiSeq i100 Series feature easy-to-use cartridges and multiple flow cell configurations for flexible sequencing options.
Operationalize informatics and drive scientific insights with Illumina Connected Analytics. Contact us for information on pricing, subscriptions, and more.
Robust DNA NGS assay interrogating 48 genes across multiple solid tumor cancer types.
Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.
Robust cfDNA liquid biopsy NGS assay, interrogating 34 genes from plasma across multiple solid tumor types.
Reach out for information about our products and services, or get answers to questions about our technology.
Your email address is never shared with third parties.
